Free Trial
NASDAQ:DBVT

DBV Technologies Q4 2024 Earnings Report

DBV Technologies logo
$8.47 -0.30 (-3.42%)
As of 05/23/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies EPS Results

Actual EPS
-$1.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$0.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

DBV Technologies' Q1 2025 earnings is scheduled for Tuesday, July 29, 2025

Earnings Documents

DBV Technologies Earnings Headlines

Combined General Meeting of June 11, 2025
52 Money Mondays for $7 (This Weekend Only)
Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’s “Most Wanted” trader, who just put the finishing touches on his brand-new Money Monday algorithm.
DBV Technologies: A Great Time To Sell
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

View DBV Technologies Profile

More Earnings Resources from MarketBeat